Orlistat
REVIVE
Empros Pharma AB · Phase 2 · Terminated · Enrollment 128
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Metformin | n/r | n/r | n/r | n/r |
| Metformin + Orlistat | n/r | n/r | n/r | n/r |
| Metformin + Topiramate | n/r | n/r | n/r | n/r |
| Topiramate | n/r | n/r | n/r | n/r |
| Metformin + Topiramate + Orlistat | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Metformin: endpoint not reported
- Metformin + Orlistat: endpoint not reported
- Metformin + Topiramate: endpoint not reported
- Topiramate: endpoint not reported
- Metformin + Topiramate + Orlistat: endpoint not reported
- Placebo: endpoint not reported